# CMS Implements Major 2026 Skin Substitute Reimbursement Policy Changes Impacting Wound Care and Vascular Surgery

> news · REPORTED · 2026-01-07

CMS began implementing significant changes to skin substitute reimbursement in 2026, introducing spending caps and tighter coverage criteria that are reshaping how wound care specialists and vascular surgeons access advanced cellular and tissue-based products for chronic wounds. Clinicians warn the policy may temporarily strain patient access, particularly for complex vascular wound populations, though some experts argue the guardrails are necessary to ensure long-term sustainability of skin substitute coverage.

About CMS / Wound Care Industry: CMS is the federal agency that administers Medicare and Medicaid, setting reimbursement policy for advanced wound care products including skin substitutes used in diabetic foot ulcer and chronic wound management.

- Company: CMS / Wound Care Industry
- Sector: medical devices
- Primary source: https://www.hmpgloballearningnetwork.com/site/wounds/qa/2026-skin-substitute-policy-changes-vascular-surgeons-perspective-access

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.